Structural insights into the lysophospholipid brain uptake mechanism and its inhibition by syncytin-2

Nat Struct Mol Biol. 2022 Jun;29(6):604-612. doi: 10.1038/s41594-022-00786-8. Epub 2022 Jun 16.

Abstract

Brain development and function require uptake of essential omega-3 fatty acids in the form of lysophosphatidylcholine via major-facilitator superfamily transporter MFSD2A, a potential pharmaceutical target to modulate blood-brain barrier (BBB) permeability. MFSD2A is also the receptor of endogenous retroviral envelope syncytin-2 (SYNC2) in human placenta, where it mediates cell-cell fusion and formation of the maternal-fetal interface. Here, we report a cryo-electron microscopy structure of the human MFSD2A-SYNC2 complex that reveals a large hydrophobic cavity in the transporter C-terminal domain to occlude long aliphatic chains. The transporter architecture suggests an alternating-access transport mechanism for lipid substrates in mammalian MFS transporters. SYNC2 establishes an extensive binding interface with MFSD2A, and a SYNC2-soluble fragment acts as a long-sought-after inhibitor of MFSD2A transport. Our work uncovers molecular mechanisms important to brain and placenta development and function, and SYNC2-mediated inhibition of MFSD2A transport suggests strategies to aid delivery of therapeutic macromolecules across the BBB.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain / metabolism
  • Cryoelectron Microscopy
  • Female
  • Humans
  • Lysophosphatidylcholines / chemistry
  • Lysophosphatidylcholines / metabolism
  • Mammals / metabolism
  • Membrane Transport Proteins / metabolism
  • Pregnancy
  • Pregnancy Proteins / chemistry*
  • Pregnancy Proteins / metabolism
  • Symporters / chemistry*
  • Symporters / metabolism

Substances

  • ERVFRD-1 protein, human
  • Lysophosphatidylcholines
  • MFSD2A protein, human
  • Membrane Transport Proteins
  • Pregnancy Proteins
  • Symporters
  • syncytin